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Background. There is little evidence regarding the management of refractory giardiasis after treatment with nitroimidazoles. 
This study estimates the proportion of persistent giardiasis in 3 hospitals in Barcelona, describes associated risk factors and genotype, 
and evaluates the efficacy rate of quinacrine in those with persistent giardiasis.
Methods. A clinical, prospective, observational study was conducted in patients with giardiasis treated with nitroimidazoles. 
Those with persistent giardiasis were provided quinacrine. Molecular characterization of Giardia isolates was performed by poly-
merase chain reaction amplification of a fragment of tpi and bg genes.
Results. Seventy-seven patients were recruited and treated with nitroimidazoles, and in 14 of 71 (20%) of patients followed 
up, Giardia persisted. Refractory giardiasis was associated with malaise (P = .007) and anorexia (P = .02), with previous giardiasis 
(P = .03), and with previous antibiotic (P = .02) or antiparasitic(P = .04) use. Quinacrine had an effectiveness rate of 100% in 
refractory giardiasis (n = 13; 95% confidence interval = 75–100). Molecular characterization showed that 17 (25%) Giardia isolates 
belonged to assemblage A, and 31 (43%) belonged to assemblage B. In refractory giardiasis, assemblage A and B were found respon-
sible in 4 and 6 cases, respectively.
Conclusions. Almost 20% of patients presented persistent giardiasis, belonging to both assemblages A and B, after nitroimidaz-
ole. Short course of quinacrine was effective in treating refractory cases. Further controlled studies should evaluate its efficacy and 
safety.
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Giardia duodenalis is one of the most common intestinal para-
sitic protozoa reported in humans [1]. The protozoon is distrib-
uted worldwide [2, 3], and estimates indicate that more than a 
billion people are at risk of giardiasis infection. It is much more 
prevalent in developing countries due to its association with 
poverty [4], where water contaminated with G. duodenalis cysts 
frequently causes travel-related giardiasis [5]. In industrialized 
countries, the infection is reemerging [6], causing waterborne 
and, to a lesser extent, foodborne outbreaks [6, 7].
Symptoms range broadly, with some infections asymptomatic 
and others causing mild to chronic diarrhea [8, 9]. Reasons for 
the variability of symptoms remain unclear although multiples 
factors have been proposed. Some findings suggest that age and 
previous Giardia exposure are associated with mucosal inflam-
mation and the intensity of symptoms [10]. Geographic and 
population variation can also affect the host immune response 
against G. duodenalis [11]. Genetic variability of Giardia strains 
has been also suggested to influence the symptomatology of 
the disease, although no association has been found between 
Giardia genotypes (assemblage A and B) and clinical symptoms 
when comparing different studies [1, 12].
Polymerase chain reaction (PCR) techniques, in addition to 
providing excellent sensitivity and specificity compared with 
microscopy and antigen-detection methods [13–15], have 
been extremely useful in recent years to improve knowledge 
and understanding of G.  duodenalis genetics. Application of 
these techniques to characterize the Giardia isolates responsi-
ble for cases of refractory giardiasis has identified assemblage 
B as responsible for these cases worldwide. To our knowledge, 
there have been no reports of refractory giardiasis produced 
by Giardia assemblage A. However, not all reported cases have 
been typed, and the limited number of those studied makes it 
difficult to establish a definitive association between assemblage 
and resistant giardiasis.
Persistence of giardiasis despite nitroimidazole therapy is also 
relatively common in patients with chronic giardiasis, account-
ing for approximately 20% of cases [16]. This may be due to 
reinfection, immunosuppression, or drug resistance [17]. There 
is no standardized second-line regimen for refractory giardiasis. 
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A second course of nitroimidazoles given for several consecu-
tive days, changing the type of antiparasitic agent, and combi-
nation therapy have been tested in these cases [17]. Quinacrine 
has been reported to have a high efficacy rate for the treatment 
of giardiasis [1], although it has been associated with severe side 
effects and poor adherence. In a previous retrospective study, 
we demonstrated a 100% efficacy rate in patients treated with 
this drug using a 7-day short-course regimen, which was not 
associated with severe adverse effects [5].
This study aims to estimate the proportion of nitroimidaz-
ole-resistant G.duodenalis in the population attending three 
Tropical Medical Units and attempt to describe the risk factors 
and the assemblages associated with the persistence of giardia-
sis. Further, the effectiveness of quinacrine in the treatment of 
these patients with resistant giardiasis is assessed.
METHODS
Study Design, Participants, and Setting
A prospective, observational study was conducted in 3 special-
ized Tropical Diseases Units in Barcelona, Spain. From July 2012 
to July 2013, all patients diagnosed with G. duodenalis attend-
ing the Tropical Medicine Unit (TMU) from Hospital Clinic, 
TMU-Drassanes, and Hospital Sant Joan de Deu in Barcelona 
were invited to participate in the study. Patients unwilling or 
unable to give informed consent were excluded. Using a 95% 
confidence level and a 20% refractory giardiasis rate established 
by previous studies [16] and considering a total of 71 patients 
that were finally included and followed-up, the final precision 
obtained was 10%. Participants were interviewed using a sem-
istructured questionnaire. Particular emphasis was put on pre-
vious travel during the last 6 months, previous gastrointestinal 
diseases, and other factors that could contribute to malabsorp-
tion. Sex, age, height (cm), and weight (kg) were recorded. All 
patients provided a stool sample before they were treated.
Standard formalin-ether concentration of all of the stool 
samples was microscopically examined for the presence of 
Giardia cysts or trophozoites. In addition, an immunocroma-
tography test was performed in fresh samples with the Stick 
Giardia test (Stick Giardia antigen kit, Operon SA). The com-
bined use of these 2 techniques aimed to achieve a greater sensi-
tivity for those cases with low number of cysts and to minimize 
the possibility of obtaining false negatives. All patients were 
initially treated with nitroimidazoles (adults and children aged 
>5 years with tinidazole 2 g for 1 day; children aged <5 years, 
with metronidazole 30 mg/kg/day for 7 days). Two control stool 
samples were collected and analyzed by microscopy and immu-
nochromatography (IC) 30 days (+/−10 days) after treatment. 
Those infections with confirmed persistence of G.  duodenalis 
(by detection of cysts in fecal samples or by IC) were defined as 
refractory giardiasis and were subsequently treated with quin-
acrine at a dose of 100 mg 3 times a day for 5 days. In children, 
the dose was adjusted to 8 mg/kg/day for 5 days.
Other routine tests such as stool cultures, microscopic obser-
vation, or parasitic serologies were conducted to investigate the 
presence of other intestinal agents that may cause intestinal 
symptoms. Human immunodeficiency virus (HIV) and immu-
noglobulin A deficiency tests were performed in those patients 
diagnosed with refractory giardiasis.
Molecular Characterization
An aliquot of all fecal samples was refrigerated and sent to the 
University of Zaragoza, where further molecular analysis was 
undertaken. Previous to DNA extraction, samples were treated 
to improve DNA quality. Giardia cysts were purified and con-
centrated using a sucrose gradient flotation method. Thereafter, 
cysts underwent 5 cycles of freezing (at −80°C for 30 minutes), 
defrosting (at 100°C for 10 minutes), and a final treatment with 
proteinase K (final concentration 100 µg/mL, overnight). When 
no cysts were observed, fresh stool samples were given the 
same pretreatment with a sucrose gradient flotation method. 
DNA extraction was carried out after digestion of cysts or on 
fresh samples using a commercial kit (Stool DNA Isolation Kit, 
Norgen Biotek Corp., Ontario, Canada) following the manufac-
turer’s instructions.
G.  duodenalis assemblage was determined by PCR of the 
triosephosphate isomerase (tpi) and ß-giardin (bg) genes fol-
lowing the protocols described by Sulaiman et al [18] and Lalle 
et  al [19], respectively. Polymerease chain reaction products 
were purified with GFXTM-PCR-DNA Gel Band Purification 
Kit (GE Healthcare) and then directly sequenced in both direc-
tions. The nucleotide sequences obtained were analyzed using 
BioEdit program (http://www.mbio.ncsu.edu/bioedit/bioedit/
html), and they were compared with the sequences deposited 
in GenBank.
The DNA sequences obtained have been deposited in the 
genetic sequence database at the National Center for Biotechnical 
Information under accession numbers JQ782391-JQ782407 
and KX468980-Kx469069.
Statistical Methods
Data were double-entered into an EpiData database, checked 
with EpiData software version 3.1, and analyzed with STATA 
version 13.
Statistical Analysis
For numerical variables, a normal distribution was tested with 
the Shapiro-Wilk normality test. Because they did not follow 
a normal distribution, they were expressed as median (inter-
quartile range [IQR]) and were compared with an unpaired 
Kruskal–Wallis test.
Categorical variables were described with numbers and per-
centages. They were compared using Monte Carlo and Fisher 
exact tests. To show the relation between patients with or without 
persistence of G. duodenalis and the rest of the variables, odds 
ratios (ORs) and 95% confidence intervals (CIs) were calculated
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A backwards stepwise multivariate logistic regression analy-
sis was performed to assess the variation of refractory giardiasis. 
Independent variables of the model were considered those that 
showed P < .20 with refractory giardiasis in the bivariate analy-
sis. The goodness of fit of this model was calculated using means 
of the Hosmer-Lemeshow test, requiring a value of P > .05. To 
avoid possible multicollinearity problems, a variance inflation 
factor <5 in all coefficients of the final model was required. The 
odds ratio with 95% confidence interval was used as the main 
estimator obtained from the statistical analyses [20].
Ethics
The study protocol and consent form were approved by the eth-
ics committee of Hospital Clínic and Sant Joan de Deu Hospital 
and the ethic committee of Gol–i-Gurina.
RESULTS
General Characteristics of the Patients
Seventy-seven patients were included in the study; 41 (53%) 
were male, and 22 [29] were children (aged <18 years). Twenty-
one (27%) were immigrants, 7 (9%) were “visiting friends & 
relatives,” and 41 (53%) were tourist or work travelers who had 
visited endemic countries. Eight patients (10%) had not trav-
elled outside Spain in the previous 6 months. Patient charac-
teristics by the geographic area where the infection was most 
probably acquired are summarized in Table  1. Almost half 
of the patients (37) acquired Giardia in Asia (75% of these 
patients had visited the Indian subcontinent), 26% acquired it 
in Africa, 14% acquired it in Latin America, and 12% acquired 
it in Europe. Travelers were the most frequent group for giar-
diasis acquired in Asia (81%), whereas immigrants were the 
predominant group for giardiasis from Latin America (55%) 
and from Africa (40%), and autochthonous patients (89%) 
were the predominant group for giardiasis acquired in Europe 
(P < .001).
Most patients reported at least 1 risk factor for Giardia acqui-
sition. Sixty-eight percent of patients had consumed raw salad 
or raw meat, and 60% of patients drank tap water on some occa-
sions, although this percentage was higher in people that had 
been in Latin America or Africa compared with Asia (P < .001). 
Tap-water consumption during travel was also more frequent 
in migrants (82.35%) and those visiting friends and relatives 
(85.71%) than travelers (55%) (P = .02).
Around a third of patients had been working with patients 
(hospitals, daycare centers, nurseries, etc), and 4% had a previ-
ous episode of giardiasis.
Only eight patients (11%) were asymptomatic, and this was 
more frequent in migrants (P =  .02). Asymptomatic infection 
was more frequent in participants coming from Latin Ameria, 
followed by Africa and Asia (P  =  .009). In autochthonous 
infections, all patients were symptomatic. Fever, abdominal 
pain, vomiting, weight loss, and malaise were more frequent in 
patients coming from Asia (P = .004, P = .001, P = .005, P = .04, 
and P = .01, respectively).
The following coinfections were observed: Entamoeba his-
tolytica/dispar [5], Ascaris lumbricoides [2], Strongyloides 
stercoralis [3], Trichuris trichiura [1], Blastocystis hominis [3] 
Schistosoma spp. [2], Cryptosporidium spp. [1], and Salmonella 
spp. [1]. However, persistence of giardiasis was not associated 
with having other concomitant intestinal parasitic infections. 
For each individual, we also calculated the number of risk fac-
tors for Giardia acquisition and the number of any other intesti-
nal parasites. No statistically significant differences were found 
in the distribution of these variables in the geographic areas 
analyzed (see Table 1).
Refractory Giardiasis
All patients were treated with tinidazole or, in the case of 
children, metronidazole. Seventy-one patients had further 
follow-up after the initial treatment, and 20 of them (28%) 
remained symptomatic (see Figure 1). In 14 patients (20%; 95% 
CI = 11%–29%), G. duodenalis was found in the stool analy-
sis. In the univariate analysis, persistent giardiasis was more 
frequent when the infection was acquired in Asia (n = 10/35; 
29%) compared with Africa (n = 3/18; 17%), Latin-America (n 
= 1/11; 9%), or Europe (n = 0/7; 0%), but this association was 
not statistically significant (P = .23).
Out of the 3 patients with HIV, 2 were cured after tinidazole 
treatment, and 1 was lost to follow-up. Refractory giardiasis was 
associated with systemic symptoms (malaise: P = .014; anorexia: 
P = .049) and, as expected, with previous antibiotic use (P = .03). 
A relevant, although not statistically significant, association was 
also found between refractory giardiasis and having traveled to 
Asia (P = .08), suffering diarrhea (0.09), having suffered previ-
ous giardiasis (P = .09), and having been treated with an anti-
parasitic (P = .10) (see Table 2).
In our model, the peristance of Giardia was not significantly 
associated with the initial treatment for giardiasis (metronida-
zole vs tinidazole), the origin of Giardia acquisition, or having 
severe symptoms . According to the multivariate analysis, the 
risk of suffering refractory giardiasis was higher in patients with 
malaise (OR = 5.02; 95% CI = 1.09–23.03), in patients who had 
undergone previous treatment (antiparasitic and/or antibiotic; 
OR = 6.19; 95% CI = 1.41–27.14), and in men (OR = 2.85; 95% 
CI = .65–12.43) (see Table 3).
Following the study protocol, 13 patients with persistent 
giardiasis took quinacrine, and tinidazole was prescribed for 1 
child who had previously taken metronidazole. This child was 
the only participant in whom G. duodenalis persisted despite 
the drug treatments, and the child improved clinically and was 
cured only after receiving quinacrine in a third-line course of 
treatment (see Figure 1). Another child completed only 3 out of 
5 days of quinacrine therapy due to adverse events, presenting 
irritability and somnolence that disappeared after stopping the 
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treatment. However, Giardia was not found in subsequent serial 
stool examinations, and he was considered cured.
Giardia Analysis and Characterization
Molecular analysis was conducted for 76 patients. A  total of 
105 sequences from 54 patients were obtained. Amplification 
was positive for 58 samples from 40 patients in whom the tpi 
gene was analyzed and for 47 samples from 39 patients in whom 
the bg gene was analyzed. Amplification of the 2 genes simul-
taneously was positive for only 24 samples from 20 patients. 
The predominant genotype was assemblage B in 31 patients 
(42%), followed by assemblage A in 17 (25%) patients. A mixed 
Table 1. Participants’ Characteristics by Subgroup
Characteristic
Continent
P value Total (n = 77)
Latin-America   
(n = 11) Asia (n = 37) Africa (n = 20) Europe (n = 9)
Male sex 5 (46) 17 (46) 13 (65) 6 (67) .40 41 (53)
Age, y
 0–18 2 (18) 4 (11) 9 (45) 7 (88) <.001 22 (29)
 19–34 6 (55) 18 (49) 3 (15) 1 (13) 28 (37)
  >35 3 (27) 15 (41) 8 (40) 0 (0) 26 (34)
Patients
 Migrants 6 (545) 6 (16) 8 (40) 1 (11) <.001 21 (27)
 Travelers 4 (36) 30 (81) 7 (35) 0 (0) 41 (53)
 Visited friends or relatives 1 (9) 1 (3) 5 (25) 0 (0) 7 (9)
 No travel 0 (0) 0 (0) 0 (0) 8 (89) 8 (10)
Risk factors for giardiasis
 Unwashed raw food 10 (100) 24 (67) 10 (59) 4 (57) .12 48 (69)
 Unsafe drinking water 9 (90) 19 (53) 14 (82) 0 (0) <.001 42 (60)
 Working care of patients 3 (30) 15 (42) 9 (47) 6 (86) .12 33 (46)
 Previous giardiasis 1 (10) 1 (3) 0 (0) 1 (13) .37 3 (4)
 Sexual contact with Giardia 0 (0) 1 (3) 0 (0) 0 (0) .78 1 (1)
 Previous intestinal disease 1 (9.09) 0 (0) 0 (0) 1 (11) .12 2 (3)
Symptoms associated with giardiasis
 Asymptomatic 4 (36) 1 (3) 3 (15) 0 (0) .009 8 (11)
 Diarrhea 5 (45) 28 (76) 14 (70) 8 (89) .15 55 (71)
 Fever 0 (0) 13 (35) 1 (5) 0 (0) .004 14 (18)
 Abdominal pain 6 (55) 30 (83) 11 (55) 1 (13) .001 48 (64)
 Vomiting 2 (18) 20 (54) 3 (15) 1 (13) .005 26 (34)
 Aerophagia 4 (36) 26 (70) 11 (8) 3 (38) .12 44 (59)
 Weight loss 3 (27) 25 (69) 7 (41) 3 (38) .04 38 (53)
 Malaise 4 (36) 24 (65) 6 (30) 1 (13) .01 35 (46)
 Anorexia 0 (0) 5 (14) 0 (0) 0 (0) .13 5 (7)
Previous treatments
 Antiparasitic 0 (0) 1 (3) 0 (0) 1 (13) .28 2 (3)
 Antibiotic 0 (0) 9 (24) 3 (15) 0 (0) .13 12 (16)
 Antidiarrhoeal 1 (9) 4 (11) 0 (0) 1 (13) .49 6 (8)
Other intestinal parasites
 Entamoeba histolytica/dispar 0 (0) 3 (8) 2 (10) 0 (0) … 5 (6)
 Ascaris lumbricoides 0 (0) 0 (0) 2 (10) 0 (0) … 2 (3)
 Strongyloides stercoralis 3 (27) 0 (0) 0 (0) 0 (0) … 3 (4)
 Trichuris trichiura 0 (0) 0 (0) 1 (5) 0 (0) … 1 (1)
 Blastocystis hominis 2 (18) 0 (0) 0 (0) 1 (13) … 3 (4)
 Schistosoma spp. 0 (0) 0 (0) 2 (10) 0 (0) … 2 (3)
 Cryptosporidium spp. 0 (0) 1 (3) 0 (0) 0 (0) … 1 (1)
 Salmonella spp. 0 (0) 1 (3) 0 (0) 0 (0) … 1 (1)
HIV 1 (9) 0 (0) 1 (6) 1 (13) .38 3 (5)
IgA immunodeficiency … 0 (0) 0 (0) 1 (100) .02 1 (12.5)
Number of risk factors 2.5 (1) 2 (1) 2 (2.75) 2 (2) .14 …
Number of other intestinal parasites 0 (4) 0 (0) 0 (0) 0 (0) .14 …
Proportions are expressed as cases/total number of patients (percent). Numerical values are expressed as median (interquartile range). Continuous variables were analyzed by using an 
independent Kruskal–Wallis test, and categorical variables were analyzed with Monte Carlo and Fisher exact tests. Bolding indicates P values statistically significant.
Abbreviations: HIV, human immunodeficiency virus; IgA, immunoglobulin A.
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infection of the 2 assemblages was observed in 6 patients, and 
no amplification despite the observance of cysts was observed 
in 18 (25%) patients. A  negative PCR test was observed in 5 
cases (7%).
Notably, out of 44 nonrefractory cases, 15 were PCR-positive 
1  month after the antiparasitic therapy (12 presented Giardia 
assemblage B, 2 presented assemblage A, and 1 was a mixed 
infection A+B), although only 3 of the patients were still symp-
tomatic. These nonrefractory cases were followed for 1 month 
after treatment as planned.
Table 2. Factors Associated With Refractory Giardiasis
Refractory giardiasis, 
no. (%)
Nonrefractory giardiasis, 
no. (%) OR (95% CI) P value
Sex
 Male 8/14 (57) 29/57 (51) 1.28 (.40–4.18) .77
 Female 6 /14 (43) 28/57 (49)
Age
 <18 y 3/14 (21) 18/57 (32) 0.59 (.16–2.24) .55
 >18 y 11/14 (79) 39/57 (68)
Patient type
 Migrant 3/14 (21) 15/57 (26) 0.76 (.20–2.94) 1.00
 Travelers 11/14 (79) 29/57 (51) 3.54 (.95–12.99) .19
 Visited friends or relatives 0 (0) 7/57 (12) … …
 No travel 0 (0) 6/57 (11) … …
Continent
 Latin-America 1 /14 (7) 10 /57 (18) 0.78 (.21–3.01) .68
 Asia 10 /14 (71) 25 /57 (44) 3.2 (.94–10.80) .08
 Africa 3/14 (21) 15/57 (26) 0.76 (.20–2.94) 1.00
 Europe 0 /14 (0) 7/57 (12) … …
Risk factors for giardiasis
 Unwashed raw food 4/12 (33) 41/53 (77) 0.15 (.04–.57) .005
 Unsafe drinking water 7/12 (58) 32/54 (59) 0.96 (.28–3.25) 1.00
 Working care of patients 4 /14 (29) 28/54 (52) 0.37 (.10–1.33) .14
 Previous giardiasis 2/13 (15) 1/54 (2) 9.63 (.82–115) .09
 Sexual contact with Giardia 0/14 (0) 1/57 (2) … …
 Previous intestinal disease 0/14 (0) 2/57 (4) … …
Symptoms of Giardia
 Asymptomatic 0/14 (0) 7/57 (12) … …
 Diarrhea 13/14 (93) 39/57 (68) 6.00 (.73–49.5) .09
 Fever 4/14 (29) 10/57 (18) 1.88 (.49–7.22) .45
 Abdominal pain 9/13 (69) 36/57 (63) 1.31 (.36–4.8) .60
 Vomiting 4/14 (29) 21/57 (37) 0.69 (.19–2.46) .76
 Weight loss 8/13 (62) 28/55 (51) 1.54 (.45–5.10) .56
 Malaise 11/14 (79) 22/57 (39) 5.83 (1.46–23.30) .01
 Anorexia 3/14 (21) 2/57 (4) 7.45 (1.12–50.30) .049
Previous treatment
 Antiparasitic 2/14 (14) 1/57 (2) 9.33 (.78–111.50) .10
 Antibiotic 5/14 (36) 6/57 (11) 4.7 (1.19–18.81) .03
Assemblage
 A 3/14 (21) 13/49 (27) 0.76 (.20–2.97) 1.00
 A+B 0/14 (0) 1/49 (0) … …
 B 6/14 (43) 23/49 (47) 0.85 (.27–2.72) 1.00
 Not typable 4/14 (29) 13/49 (27) 1.11 (.31–4.00) 1.00
Proportions are expressed as cases/total number of patients. Categorical variables were analyzed with Monte Carlo and Fisher exact tests. Odds ratios and confidence intervals were calcu-
lated by Woolf´s method. Bolding indicates P values statistically significant.
Abbreviations: CI, confidence interval; OR, odds ratio.
Table  3. Multivariate Logistic Regression Model of the Independent 
Association of Various Variables With Refractory Giardiasis
Variable OR (95% CI) P value
Sex: Man 2.85 (.65–12.43) .06
Malaise: Yes 5.02 (1.09–23.03) .04
Previous treat-
ment: Yes
6.19 (1.41–27.14) .02
Test for goodness of fit for logistic regression model: Hosmer-Lemeshow test = 1.18. P = 
.76. R2 Nagelkerke = 0.30.
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For the 14 patients with persistence of Giardia cyst in stool 
examinations after nitroimidazole therapy (13 symptomatic 
and 1 asymptomatic), 6 presented Giardia assemblage B (5 
Asia-acquired cases, 1 Latin America–acquired case). Three 
cases presented assemblage A (2 Africa-acquired cases, 1 Asia-
acquired case), and in 4 cases there was no amplification, and 
the PCR results were negative. A  specific assemblage was not 
associated with the persistence of Giardia (P > .05). Homology 
of sequences of different samples of the same patient ranged 
97%–100% for assemblage B (analyzed by amplification of 
tpi gene) and was 100% for assemblage A.  When comparing 
sequences of bg gene, there were not any single nucleotide poly-
morphims. However, identity among sequences from different 
patients and different geographical locations was observed. One 
month after quinacrine therapy, all 14 patients improved clini-
cally, and fecal antigen detection and stool examinations were 
negative for all patients but PCR was still positive in 3 cases. 
Two of these patients were further followed up, and they were 
still PCR-positive at least 2 months after the quinacrine therapy. 
Both of these patients presented assemblage B.
DISCUSSION
This work highlights an elevated proportion of refractory giar-
diasis after treatment with nitroimidazoles. It was observed in 
almost 20% of patients treated with nitroimidazoles, which is 
similar to the reported efficacy of 80%–90% elsewhere [17, 21, 
22]. Our study was not able to demonstrate any statistically sig-
nificant association with refractory giardiasis and the acquisition 
of giardiasis in Asia, as has been reported elsewhere [16, 23].
The differences in treatment failure among geographic areas 
could be attributable to acquired drug resistance, explained by 
several mechanisms. First, it has been proposed that that there 
is a geographical distribution of Giardia assemblages around 
the world, although a particular assemblage of G. duodenalis 
has not been demonstrated to be associated with refractory 
giardiasis [24]. In our study, assemblage B was predominant in 
refractory cases, consistent with other reports [25], although 
the study lacked the statistical power to demonstrate this effect. 
To our knowledge, only cases of refractory giardiasis produced 
by Giardia belonging to assemblage B have been described. 
Therefore, this work is the first to describe refractory giardiasis 
by Giardia assemblage A, proving its plausibility and suggest-
ing the importance of carrying out molecular characterization 
of Giardia populations concerning refractory giardiasis.
Second, because the levels of drug pressure may be variable in 
different parts of the world where G. duodenalis is endemic, this 
could also be a key factor in the development of drug resistance 
in Giardia strains [26].
Being a traveler or a migrant was significantly associated 
with the geographic origin where the Giardia was acquired. 
Accordingly, for most travelers, Giardia was acquired when 
travelling to Asia, particularly to India, whereas for migrants, 
the geographic origin of Giardia was mainly either Africa or 
Latin America. These findings could be explained because in 
the 3 sites where the study was carried out, >40% of travel-
ers go to Asia, and migrants are predominantly coming from 
Africa and Latin America (Travel Clinic Unit, Hospital Clinic, 
Barcelona, unpublished data).
Figure 1. Diagram of the clinical and treatment outcome of Giardia cases.
952 • JID 2017:215 (15 March) • Requena-Méndez et al
Our data are in concordance with other published data of 
imported giardiasis, in which the risk of giardiasis in return-
ing traveler was higher for the Indian subcontinent and Arab 
countries [27]. Although our study could not demonstrate that 
giardiasis acquired in Asia is more likely to be refractory to first-
line therapy, a greater proportion of refractory giardiasis was 
found in cases coming from this continent compared with the 
other regions.
Having severe symptoms such as malaise or anorexia before 
initial therapy was associated with refractory giardiasis and 
could be suggestive of higher parasitic-load infections. If this 
could be demonstrated, offering another treatment scheme, 
such as a multiple dose of nitroimidazoles, could be considered 
in these cases [1].
The evaluation of treatment efficacy in G.  duodenalis cases 
is rather complicated using the current diagnostic methods. 
Polymerase chain reaction could be helpful to identify low par-
asitic-load infections. However, our data suggest that almost 
35% of patients presented positive PCR results, despite being 
considered cured according to the clinical and stool-tests find-
ings, which is an unexpectedly high percentage compared with 
other studies that show a 100% negativization of PCR 1 week 
after a 3-day course of metronidazole therapy [28]. One pos-
sible explanation is that PCR sensitivity may be higher due to 
the molecular techniques undertaken for the genotypic char-
acterization (in our study several PCR tests were undertaken 
on the same sample, which may have increased the global sen-
sitivity). On the other hand, as reported by Martinez-Gordillo 
et  al, the intraepithelial presence of a low number of Giardia 
trophozoites is possible, resulting in a positive PCR result [29]. 
Additionally, the variability obtained for sequences of tpi gene 
and the low variability of bg gene raises questions about what 
differences exist among Giardia assemblages and the usefulness 
of genotyping methods for their characterization. The signifi-
cance of these results should be clarified in future studies.
Quinacrine demonstrated a 100% effectiveness rate, as has 
been previously described [5, 30, 31], and only 1 case of adverse 
events was observed, which led to stopping the treatment. This 
case was a child weighing <10 kg, making the optimal dose dif-
ficult to obtain due to a lack of pediatric formulation of quina-
crine. However, even with a shorter 3-day regimen, quinacrine 
was effective to eradicate the parasite.
Thus, quinacrine should be considered as a second-line drug 
treatment when available. Quinacrine is currently a medicinal 
product on a compassionate-use basis, and therefore advocacy 
is needed to include giardiasis as one of its uses. However, more 
controlled studies such as randomized trials are required to 
better evaluate the efficacy rate of quinacrine for giardiasis and 
particularly to monitor its potential side effects.
Besides the skin discoloration that has been reported, one 
of the main concerns when prescribing quinacrine is the 
occurrence of psychiatric adverse events, particularly in those 
people predisposed to such [32]. In a study conducted during 
the World War II in 7604 patients with malaria, quinacrine 
was shown to induce psychosis in 0.46% of patients [33]. 
However, the mean total cumulative dose was 2100 mg, which 
is higher than the 1500-mg total dose recommended in our 
study. Moreover, the role of preexisting malarial infection and 
previous combat experience that could have contributed to the 
clinical spectrum of the psychiatric disorders was not properly 
evaluated. Another prospective case series reported evidence 
of pronounced psychological stimulation in 5 cases after quin-
acrine administration with cumulative dose in the first day of 
1200 mg and a total cumulative dose >4000 mg, proving that 
quinacrine acts as a cortical stimulant [34]. All patients had 
a rapid resolution of symptoms, and there were no perma-
nent sequelae noted. Finally, another more recent prospective 
study described neurologic and psychiatric adverse events in 
3 patients with refractory giardiasis treated with quinacrine in 
combination with metronidazole, but again all patients were 
treated at a dose of 100 mg 3 times a day for 3 weeks, which 
is equivalent to a cumulative dose of >6300  mg [35], much 
higher than the dose recommended in our study. In another 
clinical trial conducted in children comparing mebendazole 
and quinacrine for the treatment of giardiasis, adverse events 
were frequently described in those treated with quinacrine. 
However, all adverse events were graded as mild; they did not 
affect the central nervous system nor warrant the discontinua-
tion of the treatment in any patient [36].
In our study, all patients were cured with a 5-day schedule at 
a dose of 100 mg 3 times a day. Only 1 of 14 patients suffered an 
adverse event that caused discontinuation of the therapy. The 
patient was an 11-month-old baby that presented irritability 
and sleeplessness, and it was not possible to evaluate the exis-
tence of a neuropsychiatric disorder. Further controlled stud-
ies are warranted to evaluate the efficacy and also the adverse 
effects of 3–5-day regimens of quinacrine.
CONCLUSIONS
Almost 20% of patients presented persistence of giardiasis 
despite nitroimidazole therapy. This outcome was not asso-
ciated with a particular assemblage, as Giardia assemblage B 
was predominant, but some cases produced by Giardia assem-
blage A were observed. A short course of quinacrine had 100% 
effectiveness, although the optimal dosage remains unknown, 
and the drug has not been approved to be used in giardiasis. 
Randomized controlled trials are needed to evaluate the efficacy 
and safety of quinacrine as a second-line therapy. Finally, pos-
itive PCR results may persist in asymptomatic patients appar-
ently cured according to clinical and stool-test criteria.
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